←
Miller Lab168 posts
Miller Lab avatar

Miller Lab

@MillerLabNeuro

Tim Miller lab | Washington University School of Medicine | Translational ALS and Alzheimer's disease research

◷ Joined April 2019▧ 26 Photos and videos
Miller Lab avatar
Miller Lab@MillerLabNeuro·Apr 20

It was an eventful weekend for Dr. Miller in Chicago. In addition to receiving the Potamkin Award, he was inducted as a new member into the Association of American Physicians @AAPcouncil. Congratulations, Dr. Miller!

Post attachmentPost attachment
Miller Lab avatar
Miller Lab@MillerLabNeuro·Apr 20

"I am honored and deeply grateful to the Potamkin Family, the American Brain Foundation, and the American Academy of Neurology for recognizing our work with the 2026 Potamkin Prize for Research in Pick's, Alzheimer's, and Related Diseases" – Dr. Miller #AANAM @ABFbrain @AANmember

Post attachmentPost attachment
Miller Lab avatar
Miller Lab@MillerLabNeuro·1 Nov 2023

Thank you @MtlSyndrome for your generous support! We look forward to working with you on this exciting project to develop a potential treatment for Mitchell Syndrome! neurology.wustl.edu/medical-…

Miller Lab avatar
Miller Lab@MillerLabNeuro·29 Jun 2023

Congratulations, Alex! We look forward to seeing more of your exciting and important work!

This tweet is unavailable

WashU Medicine avatar
⟳ Miller Lab retweeted
WashU Medicine@washumedicine·25 Apr 2023

BREAKING: the FDA has approved a new drug called toferson for a rare form of ALS caused by mutations in the gene SOD1. #WashUMed researcher @MillerLabNeuro, MD, PhD, led the international clinical trials. @ALSCenterWashU @biogen medicine.wustl.edu/news/drug…

Miller Lab avatar
Miller Lab@MillerLabNeuro·3 Feb 2023

3. Sulfasalazine (anti-inflammatory), telmisartan (treats high blood pressure), and #lovastatin (treats high cholesterol) were given at human-equivalent doses to ALS model mice prior to disease onset. 🐭

Miller Lab avatar
Miller Lab@MillerLabNeuro·3 Feb 2023

2. We evaluated 1,128 cases of motor neuron disease (MND) and 56,400 matched controls from a US Medicare dataset to identify the relative risk for developing MND based on medications taken before diagnosis. 🩺 This list was narrowed to 3 candidate medications: